COO Roger Adsett Buys Big Block of Insmed Shares Just Before Stock Soars 33% in the Week

Insmed’s COO Buys Deep, While the Company Rides a Bull Run

On August 10, 2026, Chief Operating Officer Roger Adsett added a sizable block of common stock, purchasing 239 360 shares at an average price of $13.67 – $17.16 – $30.46, bringing his holdings to 338 594 shares. The deal was executed while the stock was trading near its 52‑week low of $90.39, yet just days later it surged 33.6 % in the week, closing at $132.57. Adsett’s purchase, though modest relative to the firm’s $28.6 B market cap, signals confidence at the top of the organization, especially in a period of brisk upside.

What Investors Should Watch

Adsett’s buying pattern tells a story of gradual accumulation rather than a one‑off speculation. In the last two months he has sold and bought at a range of prices—from $14.56 to $174.17—yet the cumulative net position is increasing, reaching a peak of 338 594 shares. The most recent trade comes after a sharp weekly rally, suggesting that he sees the price as still undervalued relative to the company’s 12‑month outlook. Coupled with Insmed’s quarterly earnings that exceeded expectations and the upgrade of its flagship drug BRINSUPRI, the insider activity is a bullish barometer. For investors, this could mean a momentum‑driven run, especially if the company continues to deliver on its pipeline and commercial milestones.

Adsett’s Transaction Profile

Adsett’s historic transactions reveal a pattern of disciplined selling at peaks followed by strategic buying at dips. The largest sale, 88 060 shares at $14.56 on April 1, 2026, cut his position sharply but preserved cash for future purchases. He then rebuilt his stake in late April and again in May, taking advantage of price swings. His most recent trade is the largest single purchase of the year, indicating that he views the current market as an attractive entry point. This consistent buying‑after‑selling behavior aligns with a long‑term view, reinforcing the narrative that he believes Insmed’s valuation has room to grow.

Market Context and Investor Sentiment

The broader market context is favorable: Insmed’s share price has jumped over 20 % monthly and 33 % weekly, and the company’s earnings report has sparked divergent analyst calls—JP Morgan lowered its target, while Truist raised theirs—creating a debate over valuation. Social media buzz is high (11.24 % above average), though sentiment remains neutral. The combination of insider buying, a strong earnings beat, and an expanding drug portfolio positions Insmed well for sustained upside, but the negative P/E ratio and prior volatility suggest investors should remain cautious.

Bottom Line

Adsett’s latest purchase signals confidence at the executive level, and his buying pattern suggests a long‑term belief in the company’s trajectory. For investors, the insider activity, coupled with recent earnings strength, presents a potentially attractive opportunity, provided the company can translate its pipeline into consistent commercial revenue. Keeping an eye on future filing disclosures and earnings releases will be key to determining whether the current rally is sustainable.